• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Metabolism and urinary excretion of esmolol in humans.

作者信息

Achari R, Drissel D, Matier W L, Hulse J D

出版信息

J Clin Pharmacol. 1986 Jan;26(1):44-7. doi: 10.1002/j.1552-4604.1986.tb02901.x.

DOI:10.1002/j.1552-4604.1986.tb02901.x
PMID:2869058
Abstract

The urinary excretion patterns of esmolol, a short-acting beta blocker, and its major metabolite were investigated in eight healthy men after intravenous infusion of 50, 100, 200, and 300 micrograms/kg/min of esmolol for six hours and 150 micrograms/kg/min for 24 hours. Esmolol and the metabolite concentrations in urine were determined by high-performance liquid chromatography. The mean urinary recoveries of the unchanged drug were 0.64%, 0.67%, 0.69%, 0.77%, and 0.98% after the 50, 100, 150, 200, and 300 micrograms/kg/min dose, respectively. Recovery of the metabolite was independent of dose, and the overall mean recovery accounted for 73% of administered dose. The results of this study indicate that esmolol is extensively metabolized, and the extent of the metabolism is not dose related in the dosage range used. The renal route plays a very minor role in the elimination of the drug but is important for the elimination of the metabolite.

摘要

相似文献

1
Metabolism and urinary excretion of esmolol in humans.
J Clin Pharmacol. 1986 Jan;26(1):44-7. doi: 10.1002/j.1552-4604.1986.tb02901.x.
2
Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite.超短效β受体阻滞剂艾司洛尔及其主要代谢产物的动力学。
Clin Pharmacol Ther. 1983 Oct;34(4):427-34. doi: 10.1038/clpt.1983.193.
3
Pharmacokinetics of flestolol in man: preliminary data.氟司洛尔在人体中的药代动力学:初步数据。
Br J Clin Pharmacol. 1985 Dec;20(6):691-4. doi: 10.1111/j.1365-2125.1985.tb05131.x.
4
Liquid-chromatographic analysis for esmolol and its major metabolite in urine.尿液中艾司洛尔及其主要代谢物的液相色谱分析
Clin Chem. 1986 Feb;32(2):374-6.
5
Gas chromatographic-mass spectrometric assay for the ultra-short-acting beta-blocker esmolol.超短效β受体阻滞剂艾司洛尔的气相色谱-质谱分析法
J Pharm Sci. 1984 Aug;73(8):1177-9. doi: 10.1002/jps.2600730842.
6
Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.艾司洛尔,一种超短效、选择性β1肾上腺素能受体拮抗剂:药效学和药代动力学特性。
Eur J Clin Pharmacol. 1994;46(5):399-404. doi: 10.1007/BF00191900.
7
Pharmacokinetics of esmolol in anesthetized patients receiving chronic beta blocker therapy.
Anesthesiology. 1987 Mar;66(3):323-6. doi: 10.1097/00000542-198703000-00010.
8
Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus.单次静脉推注艾司洛尔的药代动力学和药效学
Clin Pharmacol Ther. 1987 Jan;41(1):112-7. doi: 10.1038/clpt.1987.19.
9
Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade.超短效β受体阻滞剂:与传统β受体阻滞剂的比较
Clin Pharmacol Ther. 1985 Nov;38(5):579-85. doi: 10.1038/clpt.1985.227.
10
Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.盐酸艾司洛尔:一种超短效β-肾上腺素能阻滞剂。
Clin Pharm. 1986 Apr;5(4):288-303.

引用本文的文献

1
Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.艾司洛尔:在快速性心律失常的短期治疗以及心动过速和高血压的短期控制中的应用评价。
Drugs. 2012 Jan 1;72(1):109-32. doi: 10.2165/11208210-000000000-00000.
2
Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease.冠心病患者中钾通道阻滞剂替地沙米与β-肾上腺素能受体阻滞剂艾司洛尔及钙拮抗剂加洛帕米的比较。
Clin Cardiol. 1998 Jul;21(7):492-502. doi: 10.1002/clc.4960210708.
3
Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
艾司洛尔。对其治疗效果和药代动力学特征的综述。
Clin Pharmacokinet. 1995 Mar;28(3):190-202. doi: 10.2165/00003088-199528030-00002.
4
Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.艾司洛尔。对其药效学、药代动力学特性及治疗效果的初步综述。
Drugs. 1987 Apr;33(4):392-412. doi: 10.2165/00003495-198733040-00004.
5
Esmolol--just another beta blocker?艾司洛尔——只是另一种β受体阻滞剂吗?
Can J Anaesth. 1992 Oct;39(8):757-64. doi: 10.1007/BF03008284.